First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II random... by Aranda, E., García-Alfonso, P., Benavides, M., Sánchez Ruiz, A., Guillén-Ponce, C., Safont, M.J., Alcaide, J., Gómez, A., López, R., Manzano, J.L., Méndez Ureña, M., Sastre, J., Rivera, F., Grávalos, C., García, T., Martín-Valadés, J.I., Falcó, E., Navalón, M., González Flores, E., Ma García Tapiador, A., Ma López Muñoz, A., Barrajón, E., Reboredo, M., García Teijido, P., Viudez, A., Cárdenas, N., Díaz-Rubio, E.

Get full text

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II stu... by Garcia-Alfonso, P, Muñoz-Martin, A, Mendez-Ureña, M, Quiben-Pereira, R, Gonzalez-Flores, E, Perez-Manga, G

Get full text

2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance ther... by Aranda, E, García-Alfonso, P, Benavides, M, Sanchez-Ruiz, A, Guillen-Ponce, C, Safont, M.J, Alcaide, J, Gomez, A, Lopez, R, Manzano, J.L, Mendez-Urena, M, Lopez, C, García-Paredes, B, Grávalos, C, García-García, T, Falco, E, Martin-Valades, J.I, Gonzalez-Flores, E, Navalon, M, Diaz-Rubio, E

Get full text